Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 | 10.07 | 16.84 | 35.56 | 20.90 |
| Expenses | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 | 9.06 | 15.96 | 34.13 | 18.66 |
| Operating Profit | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 | 1.01 | 0.88 | 1.43 | 2.24 |
| OPM % | 20.73% | 4.44% | 1.31% | 11.50% | 6.67% | 12.26% | 11.68% | 7.03% | 10.03% | 5.23% | 4.02% | 10.72% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Interest | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 | 0.40 | 0.30 | 0.34 | 0.35 |
| Depreciation | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 | 0.34 | 0.30 | 0.35 | 0.35 |
| Profit before tax | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 | 0.27 | 0.30 | 0.74 | 1.54 |
| Tax % | 31.17% | -4.00% | -39.66% | 50.00% | 28.57% | 57.69% | 33.33% | 26.67% | 29.63% | 26.67% | 28.38% | 27.92% |
| Net Profit | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 | 0.22 | 0.52 | 1.11 |
| EPS in Rs | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 | 0.17 | 0.39 | 0.84 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 75.85 | 83.37 |
| Expenses | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 71.61 | 77.81 |
| Operating Profit | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.24 | 5.56 |
| OPM % | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 5.59% | 6.67% |
| Other Income | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 |
| Interest | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.46 | 1.39 |
| Depreciation | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.36 | 1.34 |
| Profit before tax | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 1.45 | 2.85 |
| Tax % | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | 28.28% | |
| Net Profit | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 1.04 | 2.04 |
| EPS in Rs | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.79 | 1.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | 8% | 14% | 90% | ||
| Compounded Profit Growth | -5% | 21% | 5% | 423% | ||
| Stock Price CAGR | 4% | 19% | 35% | 20% | ||
| Return on Equity | 2% | 3% | 2% | 3% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 13.18 |
| Reserves | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| Borrowings | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 12.52 |
| Other Liabilities | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 10.82 |
| Total Liabilities | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 71.86 |
| Fixed Assets | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.55 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.43 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| Other Assets | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 56.26 |
| Total Assets | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 71.86 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 1.75 | 3.05 | 1.70 | 6.88 | 1.19 | 2.48 | 1.62 | 0.77 | 2.24 | 1.96 | 2.04 | -6.22 |
| Cash from Investing Activity | -1.10 | 0.23 | -1.04 | -2.21 | -0.34 | -0.84 | -3.67 | -2.44 | -2.27 | -1.21 | -2.32 | -1.13 |
| Cash from Financing Activity | -0.70 | -3.42 | -3.94 | -4.80 | -0.73 | -1.79 | 2.07 | 1.68 | 0.05 | -0.69 | 0.26 | 7.51 |
| Net Cash Flow | -0.06 | -0.14 | -3.28 | -0.13 | 0.12 | -0.15 | 0.02 | 0.01 | 0.03 | 0.06 | -0.02 | 0.16 |
| Free Cash Flow | 0.65 | 3.28 | 0.66 | 4.60 | 0.85 | 1.63 | -2.05 | -1.69 | 1.38 | 0.94 | -0.29 | -7.39 |
| CFO/OP | 33% | 51% | 38% | 152% | 36% | 78% | 65% | 26% | 60% | 59% | 59% | -137% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 | 135.37 |
| Inventory Days | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 | 102.82 |
| Days Payable | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 | 33.73 |
| Cash Conversion Cycle | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 | 204.45 |
| Working Capital Days | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 144.20 | 147.83 |
| ROCE % | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% | 5.19% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 52.13% | 55.41% | 55.41% | 55.41% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 45.08% |
| Public | 47.87% | 44.59% | 44.60% | 44.60% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 54.92% |
| No. of Shareholders | 3,957 | 4,032 | 4,734 | 4,755 | 5,073 | 5,073 | 5,252 | 5,189 | 4,718 | 4,597 | 4,464 | 4,435 |
Fundamentals
Market Cap₹ 101 Cr.
Current Price₹ 77.0
Stock P/E49.8
Book Value₹ 36.8
ROCE5.19 %
ROE2.52 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)90%
Compounded Profit Growth (TTM)423%
Standalone figures.
Valuation
Market capRs 100 Cr
Enterprise valueRs 112 Cr
P/E (TTM)48.89x
Price to book2.06x
Price to sales1.20x
EV / EBITDA19.98x
EV / EBIT26.30x
EV / sales1.34x
Earnings yield2.05%
P/E, 3-year average92.10x
P/B, 3-year average1.29x
P/E, 5-year average64.20x
P/B, 5-year average1.11x
Profitability
Operating margin (excl. other income)5.59%
Operating margin (incl. other income)5.63%
EBITDA margin6.69%
Pre-tax margin3.42%
Net profit margin2.45%
Net margin, latest quarter5.31%
ROE2.52%
ROCE5.19%
ROA1.59%
ROE, 3-year average1.56%
ROCE, 3-year average4.80%
ROA, 3-year average0.95%
ROE, 5-year average2.68%
ROCE, 5-year average5.93%
ROA, 5-year average1.49%
ROIC (approx.)5.04%
Tax rate28.28%
Other income / net worth0.06%
Growth
Sales growth (latest year)105.39%
Profit growth (latest year)246.67%
Sales CAGR, 3 years13.92%
Sales CAGR, 5 years8.12%
Profit CAGR, 3 years5.33%
Profit CAGR, 5 years-20.52%
Sales growth QoQ-41.23%
Profit growth QoQ113.46%
Sales growth YoY (latest quarter)56.20%
Profit growth YoY (latest quarter)909.09%
Per share
EPS (TTM)Rs 1.55
EPS (latest year)Rs 0.79
EPS (latest quarter)Rs 0.84
EPS, 3-year averageRs 0.50
EPS, 5-year averageRs 0.86
Book value per shareRs 36.83
Sales per shareRs 63.28
Cash flow per shareRs -4.72
Free cash flow per shareRs -5.61
Efficiency
Asset turnover1.06x
Fixed asset turnover6.57x
Inventory turnover3.58x
Inventory days102 days
Debtor days135 days
Debtors turnover2.70x
Creditor days34 days
Cash conversion cycle204 days
Working capital days148 days
Leverage
Total debtRs 13 Cr
Cash and bankRs 1 Cr
Net debtRs 12 Cr
Debt to equity0.26x
Net debt / EBITDA2.11x
Interest coverage3.05x
Owners' fund to total sources67.52%
Debt to assets17.42%
Cash flow
Cash from Operating Activity (latest year)Rs -6 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs 8 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -7 Cr
FCFE (approx.: FCF + change in debt)Rs -12 Cr
Cash from ops / profit, 5 years0.19x
Statement figures
Net sales (TTM)Rs 83 Cr
Net sales (latest year)Rs 76 Cr
Sales (latest quarter)Rs 21 Cr
Operating profit excl. other income (latest year)Rs 4 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 6 Cr
PBDT (TTM)Rs 4 Cr
Profit before tax (TTM)Rs 3 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 2 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 66 Cr
Total expenditure (latest year)Rs 72 Cr
Total income (latest year)Rs 76 Cr
Share capitalRs 13 Cr
ReservesRs 35 Cr
Shareholders' fundsRs 49 Cr
Total assetsRs 72 Cr
Net blockRs 12 Cr
Capital work in progressRs 2 Cr
InvestmentsRs 2 Cr
ReceivablesRs 28 Cr
InventoryRs 18 Cr
Other liabilitiesRs 11 Cr
Shares outstanding (crore)1.32
Ownership
Promoter holding45.08% (-9.31 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 48.9 is at the 28th percentile of its own 9.2-year range
(median 76.2, low 10.9, high 321.1).
P/B 2.06 is at the 81th percentile (median 1.46).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 538965 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.2% | -2.8% | +2.6 pts |
| 1 month | -5.0% | -6.8% | +1.8 pts |
| 3 months | +0.1% | -7.6% | +7.7 pts |
| 3 years | +138.1% | +14.2% | +124.0 pts |
| 5 years | +127.7% | +27.9% | +99.8 pts |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was -126% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 10% of total assets in 2026 |
| explain | Share dilution Share count up 32% in a year, 42% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹21 Cr +56.2% vs Jun 2025.
Net profit ₹1 Cr +909.1%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Concord Drugs Ltd?
Concord Drugs Ltd (538965) has a market capitalisation of Rs 101 Cr. at the 2026-10-01 close.
What is the P/E ratio of Concord Drugs Ltd?
Concord Drugs Ltd trades at a P/E of 49.8 on trailing twelve-month profit, at the 2026-10-01 close.
What were Concord Drugs Ltd's latest quarterly results?
In the Jun 2026 quarter, Concord Drugs Ltd sales was Rs 21 Cr (+56.2% vs Jun 2025) and net profit was Rs 1 Cr.